Cover Image
QR Code

Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China.

Published in:Expert Review of Pharmacoeconomics & Outcomes Research pp. 1 - 12
Main Authors: Chen, Weiqi, Wu, Yongyi, Zhu, Qiyun, Jiang, Bin, Si, Lei, Yang, Zhao
Format: Journal Article
Published: Taylor & Francis Ltd Aug2026
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196913100&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 196913100
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14737167
        1IHY
      jtl: Expert Review of Pharmacoeconomics & Outcomes Research
      issn: 14737167
      maglogo: N
    pubinfo:
      dt: Aug2026
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        196913100
        10.1080/14737167.2026.2718414
        196913100
      ppf: 1
      ppct: 11
      formats:
      tig:
        atl: Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China.
      aug:
        au:
          Chen, Weiqi
          Wu, Yongyi
          Zhu, Qiyun
          Jiang, Bin
          Si, Lei
          Yang, Zhao
        affil: Peking University Health Science Center
      sug:
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N